Inflammatory bowel disease - glycomics perspective.
Crohn's disease
Glycomics
Glycosylation
Inflammatory bowel disease
Pathogenesis
Ulcerative colitis
Journal
Biochimica et biophysica acta. General subjects
ISSN: 1872-8006
Titre abrégé: Biochim Biophys Acta Gen Subj
Pays: Netherlands
ID NLM: 101731726
Informations de publication
Date de publication:
10 2019
10 2019
Historique:
received:
14
01
2019
revised:
24
06
2019
accepted:
01
07
2019
pubmed:
6
7
2019
medline:
3
4
2020
entrez:
6
7
2019
Statut:
ppublish
Résumé
Inflammatory bowel disease (IBD) pathogenesis is still not well understood. It is considered to result from genetic susceptibility, environment, microbiota composition and aberrant immune response. Crohn's disease (CD) and ulcerative colitis (UC), forms of IBD, are sometimes indistinguishable by typical laboratory and clinical characteristics making timely diagnosis and subsequent therapy hit-and-miss. Glycosylation has shown a promising biomarker potential for early IBD diagnosis and effective response to treatment prediction. This mini-review briefly covers present knowledge of IBD pathophysiology, with a focus on recent research on the role of glycosylation in IBD pathogenesis and disease progression. Aberrant glycosylation significantly changes functionality of key proteins in intestinal niche and is involved in IBD etiology. Elucidating mechanisms of IBD development is one of critical goals in managing this disease. Glycans are important for fine-tuning of intestinal processes that ensure homeostatic conditions which, if disrupted, lead to IBD.
Sections du résumé
BACKGROUND
Inflammatory bowel disease (IBD) pathogenesis is still not well understood. It is considered to result from genetic susceptibility, environment, microbiota composition and aberrant immune response. Crohn's disease (CD) and ulcerative colitis (UC), forms of IBD, are sometimes indistinguishable by typical laboratory and clinical characteristics making timely diagnosis and subsequent therapy hit-and-miss. Glycosylation has shown a promising biomarker potential for early IBD diagnosis and effective response to treatment prediction.
SCOPE OF REVIEW
This mini-review briefly covers present knowledge of IBD pathophysiology, with a focus on recent research on the role of glycosylation in IBD pathogenesis and disease progression.
MAJOR CONCLUSIONS
Aberrant glycosylation significantly changes functionality of key proteins in intestinal niche and is involved in IBD etiology.
GENERAL SIGNIFICANCE
Elucidating mechanisms of IBD development is one of critical goals in managing this disease. Glycans are important for fine-tuning of intestinal processes that ensure homeostatic conditions which, if disrupted, lead to IBD.
Identifiants
pubmed: 31276732
pii: S0304-4165(19)30164-3
doi: 10.1016/j.bbagen.2019.07.001
pii:
doi:
Substances chimiques
Biomarkers
0
Blood Proteins
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1595-1601Informations de copyright
Copyright © 2019 Elsevier B.V. All rights reserved.